KBY Biotech Indexv0.0.34
Search
← Pipeline|MAY-IIT-513

MAY-IIT-513

Phase 2/3
By Mayo Clinic
Source: Trial-derived·Trials: 1
Modality
Bispecific Ab
MOA
CD47i
Target
Tau
Pathway
Complement
Schizophrenia
Development Pipeline
Preclinical
~Jan 2018
→ ~Apr 2019
Phase 1
~Jul 2019
→ ~Oct 2020
Phase 2
Jan 2021
Phase 2Current
NCT08532294
1,757 pts·Schizophrenia
2021-01→TBD·Not yet recruiting
1,757 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
2021
P2/3
Not yet…
Not yet recruiting|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT08532294Phase 2/3SchizophreniaNot yet recr...1757OS
Competitors (10)
DrugCompanyPhaseTargetMOA
NirarelsinJohnson & JohnsonPhase 2PRMT5CD47i
CevizanubrutinibJohnson & JohnsonPreclinicalFcRnCD47i
CeviglumideRocheNDA/BLAB7-H3CD47i
NVS-1475NovartisPhase 2MeninCD47i
AZN-6294AstraZenecaPhase 2/3APOC3CD47i
NVO-9087Novo NordiskPhase 1/2TauCAR-T BCMA
ZenonesiranGSKPreclinicalDLL3CD47i
TezecilimabTakedaNDA/BLATauBCL-2i
TAK-8262TakedaNDA/BLATauTNFi
AMG-7379AmgenPreclinicalDLL3CD47i